Target Name: GPM6B
NCBI ID: G2824
Review Report on GPM6B Target / Biomarker Content of Review Report on GPM6B Target / Biomarker
GPM6B
Other Name(s): Glycoprotein M6B, transcript variant 4 | GPM6B variant 4 | M6b | Glycoprotein M6B | MGC17150 | M6B | Neuronal membrane glycoprotein M6-b | MGC54284 | Neuronal membrane glycoprotein M6-b (isoform 1) | GPM6B variant 1 | Glycoprotein M6B, transcript variant 1 | GPM6B_HUMAN | protolipid M6B | Protolipid M6B | Neuronal membrane glycoprotein M6-b (isoform 4) | glycoprotein M6B

GPM6B: Potential Drug Target and Biomarker for Various Diseases

Glycoprotein M6B (GPM6B), also known as transmembrane glycoprotein 6B (TMG6B), is a protein that is expressed in most tissues of the body and plays a critical role in various physiological processes. It is a member of the glycoprotein family, which consists of proteins that are involved in cell-cell and cell-extracellular signaling. GPM6B is one of the six known isoforms of GPM6B, and its transcript variant 4 (TMG6B4) is an active form of the protein.

GPM6B is involved in many different cellular processes, including cell adhesion, migration, and signaling. It is a key regulator of cell-cell adhesion, as well as a regulator of cell migration. GPM6B is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

In addition to its role in cellular signaling, GPM6B is also a potential drug target. Several studies have suggested that GPM6B may be a useful target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the potential reasons for the potential targeting of GPM6B is its involvement in cancer progression. GPM6B has been shown to be overexpressed in many types of cancer, including breast, ovarian, and prostate cancer. It has also been shown to be involved in the regulation of angiogenesis, which is a key factor in the development of cancer.

Another potential reason for the targeting of GPM6B is its involvement in neurodegenerative diseases. GPM6B has been shown to be involved in the regulation of neurotransmitter release from neurons, which is important for the function of the brain. It has also been shown to be involved in the regulation of synaptic plasticity, which is the ability of the brain to change and adapt over time.

In addition to its potential role in cancer and neurodegenerative diseases, GPM6B may also be a potential biomarker for these conditions. Several studies have shown that GPM6B may be able to be used as a diagnostic marker for cancer, neurodegenerative diseases, and other conditions.

GPM6B has also been shown to be involved in the regulation of inflammation, which is a critical part of the immune system. It has been shown to be involved in the regulation of the production of pro-inflammatory cytokines, as well as the regulation of the production of anti-inflammatory cytokines.

In conclusion, GPM6B is a protein that is involved in many different cellular processes and has been suggested as a potential drug target for the treatment of various diseases. Its involvement in cell-cell adhesion, angiogenesis, and neurotransmission makes it a promising target for the development of new treatments. Its potential as a biomarker also makes it an attractive target for the diagnosis of certain diseases. Further research is needed to fully understand the role of GPM6B in cellular and biological processes, and to determine its potential as a drug target and biomarker.

Protein Name: Glycoprotein M6B

Functions: May be involved in neural development. Involved in regulation of osteoblast function and bone formation. Involved in matrix vesicle release by osteoblasts; this function seems to involve maintenance of the actin cytoskeleton. May be involved in cellular trafficking of SERT and thereby in regulation of serotonin uptake

The "GPM6B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPM6B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3